Group 1: Company Performance - Jiuzhou Pharmaceutical reported a revenue of 2.871 billion yuan, an increase of 3.86% year-on-year [1] - The net profit attributable to shareholders was 526 million yuan, reflecting a year-on-year increase of 10.7% [1] - The basic earnings per share stood at 0.59 yuan [1] Group 2: CDMO Industry Insights - The global CDMO market is projected to reach $168.4 billion by 2028 and $338.5 billion by 2030 [2] - China's CDMO market has grown from 16 billion yuan in 2018 to 85.9 billion yuan in 2023, with a compound annual growth rate of 39.9% [2] - The market share of Chinese CDMO companies is increasing due to competitive advantages in talent supply, labor costs, and resource support [2] Group 3: Project Pipeline and Client Engagement - Jiuzhou Pharmaceutical has a robust project pipeline with 38 projects already on the market and 90 in Phase III clinical trials [1] - The company has successfully provided services to over 80 clients from major global pharmaceutical markets, covering more than 100 active formulation projects [2] - The company has introduced over 20 new clients in the peptide and conjugate business, with a focus on diabetes and cancer treatments [3] Group 4: Global Expansion and Operational Strategy - Jiuzhou Pharmaceutical is advancing its global R&D capabilities and production capacity, with successful business progress in Japan and Germany [3] - The company aims to accelerate its global business expansion and enhance collaborative efforts to drive sustainable growth [3]